01. Doctor Overview
Dr. Corey Langer is a board-certified thoracic oncologist. He is the director of thoracic oncology at the Hospital of the University of Pennsylvania. As a graduate of Boston University’s School of Medicine, Dr. Langer completed his residency in internal medicine at Graduate Hospital. He completed his fellowships in hematology and oncology at Presbyterian Hospital and medical oncology at Fox Chase Cancer Center.
While also focusing on non–small cell and small cell lung cancer in his research, Dr. Langer has research expertise in underserved populations and novel therapeutic venues in thoracic and head and neck cancer.
In addition to Dr. Langer’s clinical work, he has been published in several peer-reviewed journals including Journal of Thoracic Oncology, Cancer and Clinical Lung Cancer.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Thoracic Oncology
Other Interests & Specialties: Adenocarcinoma of lung, pleural cancer, lung cancer, lung carcinoid tumor, head and neck cancer, esophageal cancer and immunotherapy.
Certifications, Awards & Accolades: American Board of Internal Medicine certifications in Hematology, Internal Medicine and Medical Oncology, America’s Top Doctors, America’s Top Doctors for Cancer, Best Doctors in America, Philadelphia Magazine, Newsweek, Castle Connolly America’s Top Doctors, Castle Connolly America’s Top Doctors for Cancer
Education & Experience:
- Medical Degree from Boston University School of Medicine
- Residency in internal medicine at Graduate Hospital
- Fellowship in hematology and oncology at Presbyterian Hospital
- Fellowship in medical oncology at Fox Chase Cancer Center
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. November 2020;126(22):4867-4877. doi: 10.1002/cncr.33142
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer. January 2021;22(1):58-66.e3. doi: 10.1016/j.cllc.2020.10.017
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. Journal for Immunotherapy of Cancer. October 2020;8(2):e000974. doi: 10.1136/jitc-2020-000974
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. January 2021;16(1):162-168. doi: 10.1016/j.jtho.2020.09.015
Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. Clinical Lung Cancer. September 2020;21(5):395-406. doi: 10.1016/j.cllc.2020.01.010
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. Clinical Lung Cancer. September 2020;22(1):49-57. doi: 10.1016/j.cllc.2020.08.003
Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncology Practice. September 2020;16(9):579-586. doi: 10.1200/op.20.00286
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncology. June 2020;6(6):848-855. doi: 10.1001/jamaoncol.2019.6731
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research. May 2020;26(10):2354-2361. doi: 10.1158/1078-0432.ccr-19-3663